Cota Healthcare appoints a Chief Technology Officer
New York, US-based real-world data and analytics company Cota Healthcare has appointed a Chief Technology Officer to its team, which it says will expand its capability to deliver treatment insights that improve patient outcomes and reduce the total cost of care. Bernard Chien joins Cota from Best Doctors where he also served as Chief Technology Officer.
“We are thrilled to have Bernard join our mission to enable delivery of the best possible patient outcomes, and reduce the total costs of care for populations,” said Dr Andrew Pecora, Founder and Executive Chairman of Cota. “He is a very capable technology leader – strategic, innovative and truly knows the healthcare SaaS [software as a service] space.”
In his new role, Bernard will leverage the patented Cota Nodal Address system, a digital classification methodology built by oncologists and data scientists that categorises patient factors and intended therapies to enable precision medicine at scale. He will be responsible for expanding Cota's technology vision and development roadmap, product strategy, and leading the engineering and product teams. “Cota is revealing breakthrough insights in oncology and healthcare in general,” said Dr Andrew Norden, Chief Medical Officer. “Our leadership team saw in Bernard the leadership and expertise needed to continue driving our platform into the future. We are thrilled that he is joining us.”
Bernard brings with him more than 20 years of experience as a technology leader. He previously served as Chief Technology Officer of Applause, MedVentive, and Radisphere. He said: “I am honoured to join an organisation with such a powerful mission and a truly breakthrough system for medical data extraction and analysis. I look forward to working with Cota's talented team to forge additional breakthroughs that will give providers and health systems the tools they need to make better treatment decisions, and to offer life sciences companies research grade data resources to support treatment discovery and testing.”